Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Avastin Plus Erbitux Plus Irinotecan as 2nd Line Treatment of Locally Advanced or Metastatic Colorectal Cancer in Patients Achieving Disease Progression as Best Response After 1st Line Treatment With FOLFIRI+Avastin or XELIRI+Avastin

NCT00681876 is registered in ClinicalTrials.gov with Hellenic Oncology Research Group as lead sponsor.

NCT NCT00681876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00681876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Avastin Plus Erbitux Plus Irinotecan as 2nd Line Treatment of Locally Advanced or Metastatic Colorectal Cancer in Patients Achieving Disease Progression as Best Response After 1st Line Treatment With FOLFIRI+Avastin or XELIRI+Avastin
Lead sponsor
Hellenic Oncology Research Group
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2008
Completion date
February 28, 2010
Enrollment
16 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer